Find trials
Consejos para buscar

Etiologies of Patient-Provider Discordance in Rheumatoid Arthritis

Overview

Información sobre este estudio

The purpose of this study is to explicate factors contributing to inadequate improvement in physical function and health-related quality of life despite appropriate disease-modifying treatment in persons with rheumatoid arthritis (RA) and inflammatory arthritis (IA) who meet 2010 ACR/EULAR classification criteria for RA. To do this, this study focuses on the contract of discordance, whereby the patient judges her/his disease to be either more or less active than the rheumatologist. The positive impact of this award is anticipated to be the development of a clinical framework and approach to managing the various causes of inadequate clinical improvement, ultimately improving patient-physician communication and long-term patient-centered functional outcomes.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Patients must be of age ≥ 18 years.
  • Patients must have a clinical diagnosis of IA or RA.
  • Patients must fulfill the 2010 ACR/EULAR classification criteria for RA.
  • Patients must reside within 150 miles of Mayo Clinic Rochester.
  • Patients must have had 2 visits with a rheumatologist within the past 18 months.
  • The most recent rheumatology visit must have been within 4 weeks of signing informed consent.
  • Patients must fulfill criteria for enrollment into one of the following study groups:
    • Discordant group (n = 50): ≥ 25-mm difference between the patient and provider global assessments of disease activity at the most recent clinical visit.
    • Concordant low-disease-activity group (n = 10): < 25-mm difference between the patient and provider global assessments of disease activity AND clinical judgment of low disease activity or remission at the most recent rheumatology visit.
    • Concordant high-disease-activity group (n = 10): < 25-mm difference between the patient and provider global assessments of disease activity AND clinical judgment of moderate-to-high disease activity at the most recent rheumatology visit.

Exclusion Criteria:

 

  • Patients must be able and willing to participate in all study activities.
  • Patients must be able to comprehend spoken and written English.
  • Patients must not be members of a vulnerable population.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

John Davis, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20492002

Mayo Clinic Footer